CA2501087C - Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer - Google Patents

Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer Download PDF

Info

Publication number
CA2501087C
CA2501087C CA2501087A CA2501087A CA2501087C CA 2501087 C CA2501087 C CA 2501087C CA 2501087 A CA2501087 A CA 2501087A CA 2501087 A CA2501087 A CA 2501087A CA 2501087 C CA2501087 C CA 2501087C
Authority
CA
Canada
Prior art keywords
cancer
antigen
tils
lymphocytes
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2501087A
Other languages
English (en)
French (fr)
Other versions
CA2501087A1 (en
Inventor
Ke Liu
Steven A. Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2501087A1 publication Critical patent/CA2501087A1/en
Application granted granted Critical
Publication of CA2501087C publication Critical patent/CA2501087C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2501087A 2002-10-15 2002-10-15 Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer Expired - Fee Related CA2501087C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/033243 WO2004034789A1 (en) 2002-10-15 2002-10-15 Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2501087A1 CA2501087A1 (en) 2004-04-29
CA2501087C true CA2501087C (en) 2012-01-03

Family

ID=32105950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2501087A Expired - Fee Related CA2501087C (en) 2002-10-15 2002-10-15 Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer

Country Status (4)

Country Link
EP (1) EP1558085A4 (de)
AU (1) AU2002353822B2 (de)
CA (1) CA2501087C (de)
WO (1) WO2004034789A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005336093B2 (en) 2004-10-08 2011-02-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced T lymphocyte survival
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693940B1 (de) * 1993-04-06 2002-11-13 Targeted Genetics Corporation Hybride gene zur verwendung in der herstellung von helfer-t-zell-unabhängigen zytotoxischen t-zellen
WO1999046392A1 (en) * 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines

Also Published As

Publication number Publication date
AU2002353822A1 (en) 2004-05-04
WO2004034789A1 (en) 2004-04-29
AU2002353822B2 (en) 2008-11-06
EP1558085A1 (de) 2005-08-03
CA2501087A1 (en) 2004-04-29
EP1558085A4 (de) 2006-12-06

Similar Documents

Publication Publication Date Title
EP1379670B1 (de) Aktivierte lymphozyten mit dualer spezifität und ihre verwendungsverfahren
Phan et al. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy
EP1814580B1 (de) Verfahren zur verwendung von il-21 zur adoptiven immuntherapie und zur identifizierung von tumor-antigenen
CN113631172A (zh) 用于靶向突变型ras的组合物和方法
EP3730515B1 (de) Vollhumaner t-zellrezeptor spezifisch für das 369 377-epitop aus dem her2/neu (erbb2)-rezeptorprotein
US20030219463A1 (en) T cell receptor transfer into a candidate effector cell or a precursor thereof
EP3478711B1 (de) Herv-e-reaktive t-zellrezeptoren und verfahren zur verwendung
Arienti et al. Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes
US7381405B2 (en) Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
WO2023212655A1 (en) Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20200368277A1 (en) T-cell receptor sequences for active immunotherapy
CA2501087C (en) Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
JP2004523202A (ja) 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用
CN111234004A (zh) 识别wt1抗原短肽的t细胞受体及其应用
CN113278652B (zh) 增加Survivin表达的CAR-T细胞并联合IL-15在制备抗肿瘤药物中的应用
US20220143087A1 (en) Ccr8 expressing lymphocytes for targeted tumor therapy
HK40037307B (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
Xiaobing et al. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells
HK40037307A (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
HK1247626B (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
HK1128489A (en) Methods for generating antigen-specific effector t cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181015